Herein we present an innovative approach to produce biocompatible, degradable, and stealth polymeric nanoparticles based on poly(lipoic acid), stabilized by a PEG-ended surfactant. Taking advantage of the well-known thiol-induced polymerization of lipoic acid, a universal and nontoxic nanovector consisted of a solid cross-linked polymeric matrix of lipoic acid monomers was prepared and loaded with active species with a one-step protocol. The biological studies demonstrated a high stability in biological media, the virtual absence of "protein" corona in biological fluids, the absence of acute toxicity in vitro and in vivo, complete clearance from the organism, and a relevant preference for short-term accumulation in the heart. All these features make these nanoparticles candidates as a promising tool for nanomedicine.
Herein we present an innovative approach to produce biocompatible, degradable, and stealth polymeric nanoparticles based on poly(lipoic acid), stabilized by a PEG-ended surfactant. Taking advantage of the well-known thiol-induced polymerization of lipoic acid, a universal and nontoxic nanovector consisted of a solid cross-linked polymeric matrix of lipoic acid monomers was prepared and loaded with active species with a one-step protocol. The biological studies demonstrated a high stability in biological media, the virtual absence of "protein" corona in biological fluids, the absence of acute toxicity in vitro and in vivo, complete clearance from the organism, and a relevant preference for short-term accumulation in the heart. All these features make these nanoparticles candidates as a promising tool for nanomedicine.
During
the past decades, the use of nanoscale materials for therapeutic
purposes has attracted wide interest for their relevant potential
advantages.[1,2] The possibility to introduce new therapeutic
approaches, based on the peculiar properties of these materials,[3] could help to overcome biological and metabolic
obstacles and to deliver drugs precisely to a target site.[4] In addition, nanosystems allow the combination
of different modes of action to obtain multifunctional and smart systems.[5] The development of nanomedicine agents is, however,
encountering several obstacles that arise from the innate ability
of living organisms to deal with and contrast nanosized entities.[6] Formation of the protein corona, opsonization,
mononuclear phagocyte system (MPS) capture, and physiological barriers
are all examples of the difficulties that must be addressed.[7] Additional problems arise from the long-term
fate of the nanomedicine agents, that is, clearance, accumulation,
degradation, and eventually toxicity. For these reasons, biodegradable
polymer nanoparticles (NPs) represent an interesting approach.[8] After their introduction in the organism, they
slowly decompose, producing small nontoxic fragments that are easily
excreted.[9] The most successful example
is represented by PLGA NPs.[10] In this case,
the nanoparticle matrix is an aggregate of copolymers of lactic and
glycolic acids, which undergo hydrolytic cleavage by water and esterase
enzymes.Nanoparticle degradation, whose rate is essentially
controlled
by the monomers ratio, is usually accompanied by payload (drug) sustained
release.[11,12] However, several limitations have been encountered
also with PLGA or similar nanoparticles. Their degradation starts
as soon as they are exposed to water making difficult to control the
release of the loaded drug. In addition, they must be stored in the
dried form, and the resuspension process is sometimes problematic.[13] Smart biodegradable nanocarriers stable in water
and capable of releasing their payload only once they have reached
the target are, hence, highly desirable.[14] From this point of view, disulfide-based polymers represent an interesting
solution. The disulfide bond is resistant to water, but is easily
cleaved by thiols.[15] Free thiols’
concentration is relatively low in extracellular fluids, but reaches
significant values in cytoplasm (1–10 mM)[20,21] due to the presence of the glutathione peptide.Following
such an approach, several groups have proposed organic
and hybrid nanoparticles containing disulfide groups as degradation
triggering agents.[16−19] In particular, Matile and co-workers reported the synthesis of disulfide-based
polymers via the Ring Opening Disulfide-Exchange Polymerization (RODEP)[22] both for surface-functionalization and synthesis
of cell-penetrating polymers. In this approach, cyclic disulfides,
mainly lipoic acid derivatives, undergo thiolate-initiated polymerization.
When they were functionalized with guanidinium residues,[22] the resulting polycationic polymers spontaneously
penetrate cell membranes, delivering dyes, drugs, proteins, and even
quantum dots. In the cytoplasm, the polymer is cleaved very quickly
by endogenous thiols.[15] Subsequently, RODEP
was used by Waymouth to induce cross-linking of block copolymers to
form reversible gels[23] and by Feringa and
Qu to realize polymers capable of supramolecular networking.[24] The reaction was further studied by J. Moore
who described how to control the formation of linear or cyclic polymers[25] and by Lu who used it to prepare protein–polydisulfide
conjugates.[26,27]Poly(lipoic acid) derivatives
prepared by RODEP are ideal candidates
for the formulation of biodegradable nanoparticles. Not only is lipoic
acid an endogenous molecule, but it also has antioxidant and anticancer
properties. For these reasons, it is used as a dietary supplement,
to treat various diseases such as atherosclerosis, thrombosis and
diabetes,[29,30] and even, in selected cases, as active payload
for organic or lipid nanoparticles.[15,31] As an example,
the groups of Chen and Gao formulated poly(lipoic acid) polymers into
nanoparticles, using procedures similar to those typical of PLGA nanoparticles,[28,32] and demonstrated that they are promising vectors for drug delivery
accompanied by sustained release. Yu and We formulated nanoparticles
made by a cyclodextrin-initiated cationic poly(lipoic acid) and RNA
for the codelivery of nucleic acids and drugs.[33]This paper describes a new step toward the validation
of polylipoic
nanoparticles as universal nanovectors for biomedical applications.
We demonstrate that the flexibility of lipoic acid as a precursor
is such that it makes possible the direct synthesis of cross-linked,
dye-loaded, PEG-protected polylipoic nanoparticles in a single step
starting from small molecule precursors. Advantages for large-scale
production are evident. In addition, these nanoparticles proved to
undergo degradation in the presence of thiols and revealed interesting
biological properties in preliminary biocompatibility and biodistribution
studies.
Experimental Section
Synthesis of the Precursors
Chemical reagents and solvents
were purchased from Aldrich and used without further purification.
Water was purified using a Milli-Q water purification system. Reactions
were monitored by TLC on 0.25 mm Merck silica gel plates (60 F254).NMR spectra were recorded on a AVIII 500 spectrometer (500 MHz
for 1H frequency) or on a Bruker AC-300 (300 MHz for 1H frequency).
UV–vis absorption spectra were measured on a Varian Cary 50
spectrophotometer with 1 cm path length quartz cuvettes. Fluorescence
spectra were measured on a Varian Cary Eclipse fluorescence spectrophotometer.
Both the spectrophotometers were equipped with thermostated cell holders.
ESI-MS were recorded on an Agilent Technologies 1100 Series system
equipped with a binary pump (G1312A) and MSD SL Trap mass spectrometer
(G2445D SL).Compounds 1–12 were synthesized
by standard procedures (details in the Supporting Information) and fully characterized.
Nanoparticles Synthesis
An acetone solution of the
selected precursor or precursors (20 mL, 5 mg/mL) was added dropwise
with a syringe pump (0.5 mL/min) to an aqueous solution (100 mL) of
pluronic surfactant (100 mL, 20 mM) buffered at pH 7.4 with PBS (2
mM of 2 mM of phosphate buffer) under stirring (1000 rpm). After the
addition of precursor, the solution was left stirring for 30 min.
Subsequently, 2 mL of a solution of 1-octanethiol (5 mg/mL) in acetone
was added and, after 90 min, 2 mL of a iodoacetamide (5 mg/mL) solution
in acetone was added. The milky reaction mixture was concentrated
under reduced pressure and filtered with a 0.20 μm cutoff cellulose
acetate filter. Nanoparticles were collected by centrifugation and
purified by resuspension in PBS (pH 7.4, 1 × 12 mL, 2 mM of phosphate
buffer) and in H2O (2 × 12 mL each). The nanoparticles
were stored at 4 °C as a water suspension. Stock solutions were
used for the investigation described (lyophilization, degradation,
biological experiments) upon dilution in the appropriate medium. The
same procedure was used to prepare the PEG–PLGA nanoparticles.The hydrodynamic particle size (dynamic light scattering, DLS)
and Z-potential were measured with a Malvern Zetasizer
Nano-S equipped with a HeNe laser (633 nm) and a Peltier thermostatic
system. Measurements were performed at 25 °C in water or PBS
10 mM buffer at pH 7. Transmission electron microscopy (TEM) was recorded
on a FEI Tecnai G12 microscope operating at 100 kV. The images were
registered with a OSIS Veleta 4K camera. Thermogravimetric analysis
(TGA) was run on 100 μL nanoparticle samples using a Q5000 IR
instrument from 25 to 1000 °C under a continuous air flow. NMR
spectra in the solid state were collected on a Varian 400 equipped
with a narrow bore, triple resonance T3MAS probe spinning 4 mm rotors
and operating at 1H and 13C frequencies of 400.36
and 100.68 MHz, respectively. The nominal temperature of the probe
was always set to 298 K. 13C CP-MAS spectra were acquired
at 5 kHz MAS with 1200 scans and a repetition delay up to 3 s. The
contact time for CP was 2 ms, and an acquisition time of 50 ms was
used.
Determination of Serum or Plasma Proteins Associated with NPs
NPs (50 μg/mL) were incubated at 37 °C for 30 min with
10%, 20%, or 50% HS (or HP or FCS) diluted in RPMI-1640 medium, recovered
by centrifugation (30 min, 12000 rpm at 4 °C), washed one or
three times with PBS, and dissolved in 25 μL of loading sample
buffer. NP pellets were heated at 95 °C for 5 min and loaded
in equal volumes (12 μL) on a 12% (v/v) SDS-PAGE. Proteins were
stained with the Silver Staining protocol or blotted onto PVDF membrane
(Amersham) and HRG, HSA, or Apo A1 were detected by specific antibodies
(Abnova for HRG, Calbiochem for HSS and Apo A1) by enhanced chemiluminescence
reaction.
Plasma Clotting Time
A total of 77 μL of HP were
added to 100 μL of NPs or Ludox at various concentrations in
150 mM NaCl in a 96-well microtiter plate (Sarstedt), and coagulation
was started by the addition of 23 μL of 150 mM CaCl2. The plate was incubated at 37 °C, and the changes in optic
density were read at 405 nm every 60 s for 60 times. To calculate
the mean absorbance at each time point, three wells were averaged
per sample. The time required to reach half maximal absorbance increase
(t1/2) was calculated and used for statistical
analysis.
C3a Detection
To control the complement activity, 25
μL of HS were treated with 6.25 μL of zymosan (25 mg/mL,
Sigma, prepared as described by manufacturer’s instructions)
for 30 min at 37 °C; the reaction was stopped with 25 mM EDTA.
To assess the complement activation of HS induced by NP incubation,
25 μL of HS were incubated with different concentrations of
NPs for 30 min at 37 °C. Then 1.6 μL of each sample were
mixed with 38.4 μL of water and 6.7 μL of loading sample
buffer, and 15 μL of sample were loaded onto a 12% gel. Proteins
were then blotted onto a PVDF membrane, and C3a was detected by specific
antibodies (Cabiochem) by enhanced chemiluminescence reaction.
Hemolysis
Assay
Human erythrocytes were obtained from
the human blood of healthy volunteers after elimination of buffy coats,
washed in PBS, and further treated with different NP doses (up to
100 μg/mL) in triplicate; after a 2 h incubation, samples were
centrifuged (1500 rpm for 5 min) and supernatant absorbance was determined
at 540 nm; data were expressed as a percentage with respect to positive
control (human erythrocytes incubated with water).
Cells
HeLa and Raw 264.7 cells were maintained in DMEM
(Invitrogen), supplemented with 10% FCS (Euroclone) and antibiotics
(penicillin and streptomycin, Invitrogen) at 37 °C in a humidified
atmosphere containing 5% (v/v) CO2; cells were split every
2–3 days. Human macrophages were obtained from human monocytes,
purified from buffy coats of healthy donors by means of two sequential
centrifugations on Ficoll and Percoll (GE Healthcare) gradients, and
differentiated for 7 days with 100 ng/mL macrophage colony-stimulating
factor (M-CSF, BD Biosciences) in RPMI-1640 plus 20% FCS. Total human
leukocytes were obtained from buffy coats after erythrocytes lysis
by hypotonic shock in 155 mM NH4Cl, 10 mM KHCO3, and 100 mM Na2EDTA at pH 7.4 for 3 min at room temperature.
MTT Assay
The day before the experiment, cells (HeLa,
human leukocytes, human macrophages, and mouseRaw 264.7) were seeded
onto 24-well plate (Falcon), as indicated in Figure B,C. The day of the experiment, cells were
treated with different concentrations of NPs (up to 100 μg/mL,
as indicated in Figure ) in cellular medium supplement with 10% FCS; after 24 h or 6 days
incubation, wells were sucked off and incubated with 100 μL
of MTT (Promega) at 37 °C until color development; absorbance
was red at 492 nm, and the percentage of alive cells was calculated
with respect to nontreated cells.
Figure 8
(A) Induction of hemolysis by different concentrations of F127@7-NPs doped with 10 (5% with respect to 7, average size 110 nm, PDI: 0.046 measured by DLS) or Ludox
after 2 h of incubation with fresh red blood cells; results were expressed
as a percentage with respect to total hemolysis induced by water;
*p < 0.05 with respect to the control sample.
(B) Percentage of alive cells (with respect to not treated cells)
after a 24 h treatment with different concentrations of NPs. (C) Percentage
of alive cells (with respect to nontreated cells) after a 6 day treatment
with different concentrations of NPs.
In Vivo Experiments
Health male Sprague–Dawley
rats, weighing 200 g, were injected with 2 mg/rat of rhodamine red
labeled F127@7-NPs via tail vein. Rats were housed in
a temperature-controlled environment (21–22 °C) on a 12
h light/dark cycle, with access to water and food at all times.At different time points (t0, 1 h, 3
h, 1 day, 3 days, 7 days, and 1/2 months) from injection, rats were
randomly killed and blood and organs were collected. Organs have been
removed in toto and washed in distilled water and fixed in formalin
to reduce passive dissemination on the cut surface.Experiments
were approved by the University of Padua Ethical Committee
and from Italian National Health Institute.
Neutrophil Gelatinase-Associated
Lipocalin (NGAL) Assessment
on Sera
Neutrophil gelatinase-associated lipocalin (NGAL)
was measured on sera with an enzyme-linked immunoassay (RatNGAL ELISA
kit; BIOPORTO Diagnostics, Bioexe Research Technology, Verona, Italy)
following the manufacturer’s instructions. The antibody was
specific for ratNGAL.
NGAL Expression in the Heart Tissue
Heart samples were
homogenized and solubilized in sodium dodecyl sulfate (SDS) buffer.
Protein quantification was performed using Qubit Proteinassay Kit
(Life Technologies, Monza, Italy) according to the manufacturer’s
instructions. Protein samples were mixed with a nonreducing and reducing
buffer and incubated for 5 min at either room temperature (reducing
and nondenaturating conditions) or 95 °C (reducing and denaturating
conditions). All samples were subsequently separated on a 10% gel
in SDS-PAGE and transferred onto a nitrocellulose membrane (Amersham,
Euroclone, Italy). The membrane was blocked for 1 h with 5% nonfat
milk in the TBS containing 0.5% (v/v) Triton X-100. (Sigma-Aldrich)
and incubated overnight with polyclonal goat antibodies against NGAL
(1:500, Abcam, Prodotti Gianni, Milan, Italy). Blots were developed
using the Super Signal West Femto ECL substrate (Pierce, Euroclone,
Italy). Blot image acquisition was performed using Alliance 2.7 (UVITEC,
Eppendorf, Italy) and software Alliance 2.7 1D fully automated.
Organs Biodistribution of NPs
Slices of about 3–5
mm thickness of different organs were introduce in the Alliance 2.7
(UVITEC, Eppendorf, Italy). Rhodamine red-labeled F127@7-NPs fluorescence was obtained under chroma Alliance 2.7 and was
analyzed by alliance 3D software (UVITEC, Eppendorf, Italy). The macrodistribution
analysis of NPs fluorescence signal was obtained with the same gain
and setup of the image analyzer. The intensity of the fluorescence
is represented and normalized as a pseudocolor scale bar that is consistent
for all images, and that is reported in the Figure A.
Figure 10
(A) Macroscopic
organ biodistribution of NPs. Macroscopic epifluorescence
images of NPs in different tissue sections at different time points
after tail vein injection. The intensity of fluorescence of conjugated
rhodamine red-NPs is represented, normalized, as pseudocolor scale
bar that is consistent for all images. (B) Microscopic tissue NPs
distribution: (a) Representative confocal laser microscopy images
of control organs. The green/yellow color is due to the background
of the tissue structures. In the heart image the green color, indicate
mainly the myocytes. In the kidney image, the white dashed square
indicates the glomerulus. In the liver image, the lobular liver structure
can recognized. Nuclei are counterstain with TO-PRO3 in blue. Zoom
from original magnification of 40×; (b) Laser confocal microscopy
images depicting the tissue NPs detection at t0, immediately after
i.v. injection. Note as NPs are more concentrated in heart, lung,
liver, and kidney. In the kidney image, the white dashed square indicates
the glomerulus. Nuclei are counterstain with TO-PRO3 in blue and conjugated
rhodamine-red NPs are identified by red signal. Zoom from original
magnification of 40×; (c) Representative laser confocal images
1 h after NPs injection, showing that nanoparticles (red signal) can
reach the interstitium of the organs especially the heart. Moreover,
1 h after injection, the lung showed few NPs uptake compared to the
other organs, which is in keeping with the macro-distribution analysis
in (A). Nuclei are counterstain with TO-PRO3 (in blue) and conjugated
rhodamine red-NPs were are identified in red. Zoom from original magnification
of 40×.
Laser Scanning Confocal
Microscopy Analysis and NP Localization
Fixed rat organs
were dehydrated with ethanol, cleaned with xylene,
embedded in paraffin, and sliced into 5 μm sections. One section
for each organ was counterstained with TO-PRO-3 for nuclei identification
(Invitrogen, Molecular Probes, Eugene, OR) following standard procedures.
Micrographs were taken using a laser scanner confocal microscope (Model
TCS-SL; Leica, Germany) equipped with beam splitter 488, 543, and
605 nm and FW TD 488/543/633 beam splitting excitation mirrors. Laser
scanning confocal microscopy analysis was performed keeping acquisition
parameters (laser power, aperture width, opening percentage, and gain)
constant.
Results and Discussion
Lipoic Acid Derivatives
as Nanoparticle Precursors
Several methods have been reported
for the preparation of polymeric
nanoparticles, including polylipoic ones.[28,32,34] Most of them, however, involve the use of
presynthesized polymers that are assembled to form nanoparticles.
The eventual “stealth” coating, that is, surface functionalization
with poly(ethylene glycol)[35] or similar
species,[36] requires either pre- or postfunctionalization
steps. In addition, cross-linking of the polymer chains, which should
increase the stability of the nanoparticles, is not possible. In most
of the cases (as with polyesters or polyamides), the direct synthesis
of the nanoparticles with methods such as microemulsion polymerization
is not possible because of the incompatibility of the polymer precursors
or reaction catalysts with the aqueous medium.[37]On the contrary, the RODEP reaction is fully compatible
with the presence of water.[29,22,29] In addition, Lee and co-workers[15] have
already demonstrated that nanoparticles made by lipophilic derivatives
of lipoic acid can be prepared with the nanoprecipitation method.[38,39] Based on these premises, we synthesized a set of lipoic acid derivatives
(Figure ) which, after
selection, were used for the preparation of polymeric NPs. These included
monofunctional derivatives 1 and 5, presenting
an ester and amide functional group, a series of bifunctional derivatives
of lipoic acid linked by diamine (2–4) or diol (6–8) spacers, and the
trifunctional derivative 9, presenting glycerol as a
tridentate spacer. Although some monomer precursors were not biocompatible,
in particular, some diamines, their study allowed a deeper understanding
of the structure–properties correlations controlling the nanoparticles’
formation and behavior.[37,38]
Figure 1
(A) Chemical structure
of the lipoic acid derivatives (1–9) studied in this work. (B) Schematic representation
of RODE polymerization inside pluronic-stabilized organic nanoparticles
used to form polylipoic nanoparticles.
(A) Chemical structure
of the lipoic acid derivatives (1–9) studied in this work. (B) Schematic representation
of RODE polymerization inside pluronic-stabilized organic nanoparticles
used to form polylipoic nanoparticles.Nanoprecipitation
method used to synthesize the nanoparticles.
A solution of the precursor in acetone is added to an aqueous solution
of surfactant (2 mM) and PBS buffer (pH 7.4, 20 mM). Upon mixing,
acetone diffuses, and the precursor precipitates into the micelles,
due to its hydrophobic character. Precursor polymerization is initiated
by the addition of a small amount of octanethiol in acetone and terminated
by the addition of iodoacetamide in acetone (not shown).All the precursors were prepared in good yields by standard
coupling
protocols. As usual in the case of lipoic acid derivatives, they all
showed the tendency to spontaneous polymerization. However, most of
them could be stored at dark and low temperature both in the solid
state and in solution for several weeks.[26] Diamide derivatives 2 and 3 were poorly
soluble in acetone, which is the solvent chosen for the preparation
of nanoparticles.
Nanoparticles’ Synthesis and Size
Control
Nanoparticles
made by lipoic acid derivatives were prepared according to the nanoprecipitation
protocol (Figure ).
An acetone solution of the selected precursor (5 mg/mL) was injected
into an aqueous solution of the neutral surfactant PluronicF127 (1
mM), buffered at pH 7 with PBS, under vigorous stirring.[42] The volume ratio between the organic and aqueous
solutions was 1:10. Upon mixing, the diffusion of the organic solvent
in water induced the immediate aggregation of the insoluble precursors
and the formation of surfactant-stabilized organic nanoparticles.
The RODEPpolymerization of the lipoic acid derivatives was induced
by the addition of a lipophilic thiol (1-octanethiol). Finally, the
polymerization reaction, as well as the possible excess of 1-octanethiol,
was quenched with 2-iodoacetamide (Figure ).
Figure 2
Nanoprecipitation
method used to synthesize the nanoparticles.
A solution of the precursor in acetone is added to an aqueous solution
of surfactant (2 mM) and PBS buffer (pH 7.4, 20 mM). Upon mixing,
acetone diffuses, and the precursor precipitates into the micelles,
due to its hydrophobic character. Precursor polymerization is initiated
by the addition of a small amount of octanethiol in acetone and terminated
by the addition of iodoacetamide in acetone (not shown).
The formed polymeric NPs were purified
by centrifugation and resuspended in water or PBS buffer. transmission
electron microscopy and dynamic light scattering (DLS) analyses revealed
average diameters ranging from 100 to 150 nm and a quite homogeneous
size distribution (Figure ). Similar results (see infra) were obtained with all the
precursors tested. Larger NPs (average diameter of 200–300
nm) were obtained when the volume ratio of the organic and water solutions
was increased to 1:1.
Figure 3
(A) TEM micrograph and (B) nanoparticle size distribution
(number
weighted) determined by DLS of F127@9-NPs (average size
102 nm, PDI: 0.088 measured by DLS). (C) Nanoparticle size distribution
determined by TEM.
(A) TEM micrograph and (B) nanoparticle size distribution
(number
weighted) determined by DLS of F127@9-NPs (average size
102 nm, PDI: 0.088 measured by DLS). (C) Nanoparticle size distribution
determined by TEM.The formation of cross-linked
polylipoic NPs by RODEPpolymerization
was first confirmed by cross-polymerization magic angle spinning (CP-MAS)
solid state 13C NMR. We compared the spectrum of a sample
of dried NPs, prepared with precursor 9 and the F127Pluronic surfactant (F127@9-NPs), with that of pure F127
and 9. The NMR spectra of F127 (Figure a) and 9 (Figure c) showed sharp signals, as expected for
compounds in the physical state of viscous liquids or gels. In the
case of F127@9-NPs (Figure b), signals corresponding to the spins of
monomer 9 were instead broad and substantially weaker.
Signals relative to F127 remained sharp, but the intensity of the
signal at 18 ppm is substantially lower than in the pure sample. Cross-polarization
experiments enhance the signals of mobile moieties with respect to
more rigid ones. Hence, the mobility of 9 residues in
the nanoparticles sample was substantially reduced with respect to
the surfactant molecules, suggesting the polymerization of the lipoic
acid moieties in the particles’ cores. Also, the surfactant
signals provided relevant information. F127 is a diblock copolymer
composed by three fragments: two hydrophilic terminal poly(ethylene
glycol) portions (PEG, 100 units each, PEG4400) and a hydrophobic
poly(propylene glycol) inner portion (PPG, 65 units).[40] Due to its structure, it adopts a U shape when it forms
a micellar aggregate. The fact that the signal at 18 ppm, relative
to the inner poly(propylene glycol) portion of F127, was less intense
with respect to the pure sample suggests that this portion experiences
at least partially a mobility decrease, with the consequent signal
broadening. This evidence confirmed that the surfactant remained adsorbed
on the nanoparticles’ surface or even entangled in the polymer
matrix, providing the nanoparticles with a poly(ethylene)glycol coating.
This should ensure “stealth” properties to the NPs,
that is, the ability to avoid the absorption of plasma proteins and
consequently escape macrophage capture.[46] Moreover, Pluronic surfactants have been approved by the FDA as
a safe and inert additive for medical formulations.[41]
Figure 4
CP-MAS SS-13C-NMR of (a) pure F-127, (b) lyophilized
F127@9-NPs (average size 132 nm, PDI: 0.082 measured by DLS), and
(c) pure 9.
CP-MAS SS-13C-NMR of (a) pure F-127, (b) lyophilized
F127@9-NPs (average size 132 nm, PDI: 0.082 measured by DLS), and
(c) pure 9.It is relevant to note
that lipoic acid derivatives can undergo
polymerization even in the absence of initiators. Hence, to evaluate
if precursors polymerization is the result of the addition of the
thiol initiator, we compared the properties of F127@9 nanoparticles produced with and without the addition of initiator
and quencher. Size of the nanoparticles upon prolonged incubation
in water was monitored with DLS (Table S2). In the case of nanoparticles produced with the initiator, no relevant
variations of both size and polydispersity index (PDI) were detected
after 21 days. On the other hand, nanoparticles prepared without the
initiator underwent a relevant size increase, doubling the average
hydrodynamic diameter in 21 days. In addition, PDI substantially increased.
Swelling, as well as decreased electron density, was confirmed also
by TEM analysis (Figure S18). The reasons
for the observed swelling are still unclear, but it appears quite
evident that the thiol-initiated RODEP led to the formation of more
rigid and stable nanoparticles.We could determine the amount
of F127 bound to the nanoparticles
by performing elemental analysis on several batches of F127@7-NPs and F127@9-NPs (Table S1). Using the sulfur content to separate the contribution
of the precursors and the surfactant, we could determine that the
F127 content was on average 22.6% (F127@7-NPs, 180 nm)
and 28.5% (F127@9-NPs, 144 nm). Tentative calculations
performed assuming the density of 0.6 g/cm3 for the polylipoic
cores indicated a footprint of 4.1 ± 1.1 and 4.0 ± 1.6 nm2 respectively, and an average distance between the grafting
points of 2.3 nm in both cases. The Flory radius of PEG4400 is 5.5 nm;[43] consequently, the footprint
values obtained indicate a brush PEG shell.[43]Having established a general protocol to prepare cross-linked
polydisulfide
nanoparticles, we investigated the influence of the synthetic parameters
on the particles size. First, we explored the role of the chemical
structure of the pluronic surfactant used on the NPs assembly (Table ). The preparation
of NPs was repeated using F-68 (featuring a PEG/PPG/PEGratio of 76–29–76)
and P-123 (ratio of 20–70–20) and precursor 8. DLS analysis showed that nanoparticles prepared with surfactants
F-68 and F-127 had similar average sizes and distributions; meanwhile,
the use of surfactant P-123 did not lead to the formation nanoparticles
stable enough to survive the purification procedure. This suggested
that a high PEG/PPGratio in the surfactant is needed to efficiently
stabilize the nanoparticles.
Table 1
Average Hydrodynamic
Size and Dispersion
(Expressed as Polydispersity Index, PDI) of Nanoparticles Prepared
from Precursor 8 and Different Pluronic Surfactants
surfactant
size (nm)
PDI
F-68
115 ± 36.7
0.102
F-127
141 ± 42.3
0.090
P-123
26.4 ± 10.2
0.149
Surfactants F-68 and F-127 were then studied for the preparation
of nanoparticles with the acetone-soluble precursors 5, 7, 8, and 9 (Table and Figures S10–S17), all featuring an ester group. In most of the
cases, we obtained similar average diameters of the NPs and relatively
narrow distributions (indicated by the polydispersity index, PDI)
with the two surfactants.
Table 2
Average Hydrodynamic
Size and Dispersion
(Expressed As Polydispersity Index, PDI) of Nanoparticles Prepared
from Precursors 5–9 and Different
Pluronic Surfactants
monomer
surfactant
size (nm)
PDI
5
F-68
198 ± 84.2
0.181
F-127
137 ± 41.6
0.092
7
F-68
122 ± 16.4
0.018
F-127
121 ± 19.9
0.027
8
F-68
119 ± 34.1
0.082
F-127
132 ± 44.8
0.115
9
F-68
96.9 ± 36.4
0.141
F-127
91.2 ± 28.4
0.097
Noticeably, monofunctional precursor 5, produced NPs
with larger average size and broader distribution when used with F-68
as surfactant. This effect could be ascribed to the fact that monomer 5 cannot form a cross-linked polymeric network at difference
from precursors 7–9. However, we
noticed that a small size trend is observed by moving from 5 to 9, that is, by increasing the molecular weight and
hydrophobicity of the precursors. In the case of organic nanoparticles
prepared with similar precursors, it has been reported that size and
hydrophobicity of the precursors may have an effect on the size of
the nanoparticles leading to the formation of smaller particles in
the nanoprecipitation phase.[29] In our case,
this effect, even if relatively modest, was confirmed, suggesting
that precursor molecular weight is the main parameter affecting the
final size of the nanoparticles.The “amide” precursors 1–4 were not investigated in detail since
only 1 and 4 were revealed to be soluble
in acetone. However,
preliminary experiments showed that precursor 8 behaved
similar to precursor 5.We also studied the effect
of the concentration of the precursor
on the size of the nanoparticles prepared with monomers 7 and 9 and the surfactant F127 (Table ). The results indicated a generally small
dependence of the NP size from the precursors concentration. However,
in the case of precursor 7, larger particles were obtained
at selected precursor concentrations (4 and 3 mg/mL). This suggests
that other synthetic parameters not investigated here, in particular,
the mixing efficiency, can be relevant in determining the size of
the nanoparticles formed.[37,38]
Table 3
Average Hydrodynamic Size and Dispersion
(Expressed As Polydispersity Index, PDI) of Nanoparticles Prepared
from Precursors 8 and 9 and F127 Surfactant
Using Different Precursor Concentrations
monomer
monomer
concn (mg/mL)
size (nm)
PDI
7
5
127 ± 54.9
0.187
4
166 ± 74.4
0.201
3
162 ± 58.9
0.132
2
129 ± 59.3
0.211
1
136 ± 34.4
0.064
9
5
91.2 ± 28.4
0.097
4
93.3 ± 33.4
0.128
3
85.2 ± 29.8
0.122
2
90.2 ± 30.7
0.116
1
81.4 ± 29.1
0.128
Fluorescent-Doped Nanoparticles
Fluorescent labeling
of the NPs was performed to directly study their biological localization.
To avoid potential interference arising from autofluorescence of biological
structures,[44] fluorescence labels featuring
long-wavelength absorption and emission were selected and conjugated
with lipoic acid derivatives. We focused our attention to three molecules:
rhodamine (10), cyanine dyeIR-775 (11),
and porphyrin (12) (Figure ). These three dyes cover a large range of
excitation and emission wavelengths in the visible and NIR regions.[45] Indeed, the rhodamine derivative 10 emits at 593 nm (excitation 561 nm), the cyanine 11 at 816 nm (excitation at 775 nm), and the porphyrin 12 at 651 nm (excitation at 417 nm). Derivatives 10–12 were prepared as described in the Supporting Information and effectively copolymerized with compound 7, resulting in the corresponding dye-doped nanoparticles.
In each case, the emission of doped nanoparticles is similar to that
of the corresponding monomer unit (Figures S4, S6, and S8).
Figure 5
Fluorescent lipoic acid derivatives used for nanoparticle
labeling.
Fluorescent lipoic acid derivatives used for nanoparticle
labeling.
Thiol-Induced Degradation
As mentioned before, polydisulfide
NPs are expected to undergo depolymerization in the presence of high
concentrations of thiolates[22b] (e.g., in
glutathione and cysteine inside tumor cells). Therefore, we studied
the effect of incubation with dithiothreitol and glutathione as reducing
agents on size and NPs.Rhodamine-labeled F127@7-NPs and F127@9 were incubated with 10 mM dithiothreitol (DTT) or
glutathione (GSH) at 37 °C for 1 and 24 h and their size and
morphology were monitored via TEM and DLS. TEM analysis revealed fast
degradation of the NPs, which lost their structure and formed small
fragments or aggregates already after 1 h of incubation (Figure A). Interestingly,
degradation of less cross-linked F127@7 NPS was faster
than that of F127@9 NPs, suggesting that more extended
cross-linking might provide some resistance to the loss of structure.
No degradation was observed after 1 h incubation with 1 mM GSH at
37 °C (Figure S20) both with F127@7 and F127@9. Prolonged incubation (24 h) at
10 mM thiols concentration resulted in extensive nanoparticles degradation
(Figure B). In the
case of NPs incubated with a lower (1 mM) GSH concentration, degradation
was detected after 30 days of incubation.
Figure 6
(A) TEM micrographs of
F127@7-NPs doped with 10 (5% with respect
to 7, average size 120 nm,
PDI: 0.088 measured by DLS, left) and of F127@9-NPs doped
with 10 (5% with respect to 9, average size
102 nm, PDI: 0.088 measured by DLS; right) incubated at 37 °C
for 1 h in 10 mM glutathione. (B) TEM micrographs of F127@7-NPs doped with 10 (5% with respect to 7, average size 110 nm, PDI: 0.046 measured by DLS) incubated at 37
°C for 24 h in 10 mM glutathione (left) and 10 mM DTT (right).
Scale bars: 1 μm (A), 500 nm (B, left), and 2 μm (C, right).
(A) TEM micrographs of
F127@7-NPs doped with 10 (5% with respect
to 7, average size 120 nm,
PDI: 0.088 measured by DLS, left) and of F127@9-NPs doped
with 10 (5% with respect to 9, average size
102 nm, PDI: 0.088 measured by DLS; right) incubated at 37 °C
for 1 h in 10 mM glutathione. (B) TEM micrographs of F127@7-NPs doped with 10 (5% with respect to 7, average size 110 nm, PDI: 0.046 measured by DLS) incubated at 37
°C for 24 h in 10 mM glutathione (left) and 10 mM DTT (right).
Scale bars: 1 μm (A), 500 nm (B, left), and 2 μm (C, right).DLS experiments, on the other hand, showed no apparent
changes
in the average diameter upon 24 h incubation.The apparent discrepancy
between the two experiments may be explained
by the difference in the condition of analysis. The DLS measurements
are performed in aqueous solutions, and the thiolate-induced depolymerization
is expected to convert the cross-linked polymer chain into the lipoic
monomers,[22] which are still water-insoluble
molecules. Hence, depolymerization may simply turn cross-linked polymeric
nanoparticles into organic nanoparticles, with no apparent effect
on the hydrodynamic size (Figure S19).
This hypothesis is confirmed by the behavior observed with nanoparticles
prepared in the absence of the thiol initiator, as previously discussed,
which showed a relevant size increase only upon several days of incubation
in water. On the other hand, TEM is performed after solvent evaporation
and under high vacuum. In such conditions, molecular aggregates and
monomers are expected to dissociate or, at least, lose their integrity
as long as depolymerization proceeds and the cross-linked network
degrades. Hence, degradation is positively observed with this technique.We also preliminarily assessed the release of dye 10 from the nanoparticles in the presence of thiols. F127@7 and F127@9 NPs were incubated at 37 °C in the
presence of 1 and 10 mM GSH for 1 h. Then, nanoparticles were isolated
by centrifugation, resuspended, and the concentration of remaining
dye measured. After incubation with 1 mM GSH, no dye leaching was
detected. On the other hand, after incubation with 10 mM GSH, the
dye loading in the nanoparticles decreased by 12% and 8%, respectively,
for F127@7 and F127@9 NPs (Table S4).
Freeze-Drying Stability
To confirm
their potential
as drug carriers, polymeric nanoparticles should demonstrate a high
stability upon storage. Freeze-drying is a commonly used technique
to store pharmaceutical preparations.[42] Therefore, we tested the nanoparticles stability of rhodamine-labeled
F127@7-NPs (average size 84 nm, PDI: 0.08 measured by
DLS) toward lyophilization in the presence of different amounts of
trehalose (5%, 10%, 25%, and 30%) as a lyoprotectant (Figure S22).[46]Sugar molecules should interact with the solvent and PEG shell by
hydrogen bonding, protecting the latter from the loss of adsorbed
water molecules.[47] Remarkably, the lack
of the lyoprotectant resulted in a drastic increase in the nanoparticles’
dimension by 20-fold. On the other hand, the use of trehalose prevents
particles aggregation. Reconstituted suspensions analyzed by DLS featured
similar average diameter and slightly larger PDI than the as prepared
one, indicating only minor NPs aggregation. These results confirmed
the efficacy of the lyophilization technique for long-term preservation
and storage of these polylipoic particles.
Interaction with Serum/Plasma
Proteins
The formation
of a hard corona, a set of strongly bound biomolecules on the surface
of NPs, is a possible source of interfering effects and adverse reactions
in biological environments.The protein corona has been indeed
reported to affect cell interactions and the targeting selectivity
of nanoparticles.[48] In addition, some NP-bound
proteins could favor inflammatory or procoagulant effects and the
clearance by RES macrophages, especially the liver Kupfer cells.[49] According to the most recent literature, polymer
coating in many cases does not prevent protein binding, but controls
the selective recruitment of a small pool of proteins that are, in
turn, responsible for the nanoparticle’s properties.[50−53]The protein corona formed on our nanoparticles was investigated
using SDS-PAGE analysis followed by sensitive silver staining. The
experiment revealed that F127@7-NPs, preincubated with
human serum (HS) up to quasi-physiological concentrations (50% v/v),
were virtually free of bound serum proteins upon few washes in protein-free
PBS (Figure A, left
panel). The extent of protein association to poly(lipoic acid) nanoparticles
after incubation with human plasma, human serum, and FCS was not dissimilar,
or even reduced, compared to the one observed with 50:50 poly lactic-co-glycolic acid (PLGA) NPs (average size 95 nm, PDI 0.27
measured by DLS), functionalized with PEG5000, used as
a regulatory-approved NP benchmark[57] (Figures S23 and S24). On the contrary, amorphous
Ludox-NPs, here used as a hard corona-endowed NP control, recruited
and retained the major corona protein HRG even after washings, as
previously demonstrated.[53]
Figure 7
(A) silver staining (left
panel) and Western blot analysis (right
panel) of proteins associated to F127@7-NPs doped with 10 (5% with respect to 7, average size 110 nm,
PDI: 0.046 measured by DLS) or Ludox after 30 min incubation at 37
°C with different concentrations of HS (human serum); (B) the
time corresponding to half maximal coagulation of HP deduced by kinetics
curves in the presence of indicated NP and Ludox concentrations are
shown; *p < 0.05; **p < 0.01;
***p < 0.001 with respect spontaneous coagulation;
(C) C3a detection by Western blot in HS treated with Zymosan (positive
control) or different NP concentrations.
(A) silver staining (left
panel) and Western blot analysis (right
panel) of proteins associated to F127@7-NPs doped with 10 (5% with respect to 7, average size 110 nm,
PDI: 0.046 measured by DLS) or Ludox after 30 min incubation at 37
°C with different concentrations of HS (human serum); (B) the
time corresponding to half maximal coagulation of HP deduced by kinetics
curves in the presence of indicated NP and Ludox concentrations are
shown; *p < 0.05; **p < 0.01;
***p < 0.001 with respect spontaneous coagulation;
(C) C3a detection by Western blot in HS treated with Zymosan (positive
control) or different NP concentrations.Additional Western Blot (Wb) analysis, performed on typical corona-forming
serum proteins albumin and Apo A1, as well as on HRG, also indicated
a nonsignificant absorption of these proteins to F127@7-NPs (Figure A, right
panel). Similar conclusions could be drawn when experiments were performed
in human citrated plasma (HP) or in fetal calf serum (FCS; Figure S23A,B). Even in these two media, NPs
did not show a strong protein binding propensity.The binding
to nanoparticles of selected plasma components may
also trigger self-amplifying proteolytic cascades, primarily the coagulation
process[54] and the complement activation.[55] These may be responsible for severe adverse
reactions, like disseminated intravascular coagulation and inflammation
and could also accelerate the clearance by RES macrophages.However, consistently with the experiments showing a reduced protein
recruitment, F127@7-NPs also showed a poor ability to
trigger fibrin activation in human plasma and to form a clot via the
FXII-dependent contact cascade, after reintroduction of physiological
Ca2+. On the contrary, in the same conditions, the positive
control Ludox-NPs was extremely effective (Figures B and S25).[56] Moreover, the formation of the C3a anaphylotoxin,
the active peptide released upon C3 cleavage and diagnostic of complement
cascade activation, assayed by Wb after incubation of NPs with human
serum was not increased compared to negative control (no agonist)
by F127@7-NPs (Figure C).We conclude that poly(lipoic acid)-based
NPs do not form a stable
protein corona and do not activate the contact coagulation and the
complement cascades in human plasma/serum. As mentioned, several studies
have recently demonstrated that densely PEGylated nanoparticles still
retain the ability to recruit proteins from serum.[58] The observation here reported that F127@7-NPs,
which also feature a PEGylated surface, do not form a hard corona
suggests that also the core material (not completely masked by the
coating) might play a role in protein recruitment. The combined effect
of the coating and the core material properties make these nanoparticles
peculiarly inert toward the proteins present in human blood plasma.
Compatibility of Poly(lipoic acid)-Based NPs with Blood Cells
To further test in vitro the hemocompatibility of our NPs, we analyzed
the possible induction of human erythrocytes lysis. No significant
hemoglobin release was determined by F127@7-NPs, while
in the same conditions Ludox-NPs were very effective and induced full
erythrocyte disruption at the maximal dose tested (100 μg/mL; Figure A).(A) Induction of hemolysis by different concentrations of F127@7-NPs doped with 10 (5% with respect to 7, average size 110 nm, PDI: 0.046 measured by DLS) or Ludox
after 2 h of incubation with fresh red blood cells; results were expressed
as a percentage with respect to total hemolysis induced by water;
*p < 0.05 with respect to the control sample.
(B) Percentage of alive cells (with respect to not treated cells)
after a 24 h treatment with different concentrations of NPs. (C) Percentage
of alive cells (with respect to nontreated cells) after a 6 day treatment
with different concentrations of NPs.Subsequently, the presence of acute cytotoxic effects of F127@7-NPs after a 24 h incubation with pooled blood leukocytes,
human and murine macrophages and the HeLa epithelial cell line, was
tested by estimating their metabolic activity (MTT assay; Figure B). Again, and consistent
with hemolytic assays, no effects were observed. Accordingly, the
proliferation rate of HeLa cells, seeded at low density and allowed
to grow in the presence of NPs for up to 6 days, was also not affected
(Figure C).We conclude that our poly(lipoic acid)-based NPs lack acute membrane-damaging
and cytotoxic effects on red and white blood cells, but also on macrophages
and epithelial cells. In addition, the proliferation rate of HeLa
cells was perfectly normal after prolonged incubation with NPs, suggesting
their biocompatibility even upon chronic cellular exposition.
Interaction
of NPs with Serum and Tissue In Vivo
Hemocompatibility
and toxicity of our NPs were also studied in vivo in rat models. First,
we analyzed the amount of serum neutrophil gelatinase-associated lipocalin
(NGAL), a 25 kDa protein considered to be a sensitive biomarker for
acute kidney injury and nonrenal organ damage. Tissues injured by
ischemia or other toxic insults release NGAL as a protective agent
against oxidative stress and as an activator of the regeneration processes.As a consequence, high serum NGAL levels are diagnostic of chronic
organ damage.[59] Upon injection of 2 mg/ratF127@7-NPs, the basal rat serum NGAL levels (224.5 ±
7.71 ng/mL) slightly increased after 3 h (375.3 ± 11.6 ng/mL),
to remain constant, albeit with relevant variability, up to 1 day
(370.5 ± 209.5 ng/mL). This increase is smaller than those (up
to 3-fold) observed with other factors inducing permanent damages.[59] NGAL levels returned to normal basal values
after 7 days (201.6 ± 37.69 ng/mL) and remained constant for
at least 2 months (194.0 ± 4.0 ng/mL; Figure A).
Figure 9
Evaluation of NPs toxicity in vivo. (A) sNGAL
values on rat sera
at different time points after F127@7-NPs tail vein injection.
Note that sNGAL levels at 3 h until 1 day are significantly elevated
compared to controls (375.3 ± 11.6 and 370.5 ± 209.5 ng/mL
3 h and 1 day, respectively). At 3/7 days to 2 months sNGAL levels
returns to control values (201.6 ± 37.69 vs 224.5 ± 7.71
ng/mL, data for 7 days and basal rat level, respectively); (B) NGAL
tissue-expression in the heart. Western blot in nonreducing conditions
reveals an increase of 25 kDa bands, which correspond to monomers
of NGAL protein at 3 h and 1 day from NPs injection. No NGAL protein
bands have been noticed from 3 days up to 2 months after NPs injection.
Evaluation of NPs toxicity in vivo. (A) sNGAL
values on rat sera
at different time points after F127@7-NPs tail vein injection.
Note that sNGAL levels at 3 h until 1 day are significantly elevated
compared to controls (375.3 ± 11.6 and 370.5 ± 209.5 ng/mL
3 h and 1 day, respectively). At 3/7 days to 2 months sNGAL levels
returns to control values (201.6 ± 37.69 vs 224.5 ± 7.71
ng/mL, data for 7 days and basal rat level, respectively); (B) NGAL
tissue-expression in the heart. Western blot in nonreducing conditions
reveals an increase of 25 kDa bands, which correspond to monomers
of NGAL protein at 3 h and 1 day from NPs injection. No NGAL protein
bands have been noticed from 3 days up to 2 months after NPs injection.To understand if the moderate and short reaction
evidenced by the
serum NGAL levels was related to any relevant tissue toxicity, we
further evaluated the expression of NGAL protein in the cardiac tissue
of the injected rats using Western Blot assays. Three isoforms of
NGAL are usually isolated from
tissues: the 25 kDa monomer (which is detected also in the serum),
a 45 kDa disulfide-linked homodimer, and a 135–150 kDa heterodimer.
The latter form is pathologically very relevant. Indeed, it consists
of two components: a NGAL monomer covalently bound to a matrix metalloproteinase
(in particular, MMP9).[59] The formation
of the dimer blocks the metalloproteinase activity, leading to collagen
breakdown with negative heart remodeling. Western Blot analysis (Figure B) did not show any
NGAL bands at 130–150 kDa, indicating the absence of a complex
formation with MMP9 and, consequently, of a heart negative remodeling
at any time from NPs injection (Figure B, blue square).Moreover, in the heart of the
injected rats, NGAL protein showed
an increase of the 25 kDa form at 3 h and 1 day after NPs injection
(Figure B, red square),
in agreement with the observations performed on serum. This band quickly
faded at longer times, to reach basal levels after only 3 days.These results indicate that our poly(lipoic acid)-based NPs, not
eliciting a significant and stable tissue toxicity over time, may
be suitable as nanovectors also in heart targeting.
Biodistribution
Study In Vivo
We finally assessed the
biodistribution of nanoparticles after injection by fluorescence imaging
of sliced organs. This technique allows the visualization of the spatiotemporal
distribution of NPs in different tissues. Specifically, the time-dependent
biomolecular distribution imaging of rhodamine-labeled F127@7-NPs was obtained using Chroma Alliance 2.7 and its 3D software.
Results, reported in Figure A, show the NPs distribution
and clearance in the different organs at different times.(A) Macroscopic
organ biodistribution of NPs. Macroscopic epifluorescence
images of NPs in different tissue sections at different time points
after tail vein injection. The intensity of fluorescence of conjugated
rhodamine red-NPs is represented, normalized, as pseudocolor scale
bar that is consistent for all images. (B) Microscopic tissue NPs
distribution: (a) Representative confocal laser microscopy images
of control organs. The green/yellow color is due to the background
of the tissue structures. In the heart image the green color, indicate
mainly the myocytes. In the kidney image, the white dashed square
indicates the glomerulus. In the liver image, the lobular liver structure
can recognized. Nuclei are counterstain with TO-PRO3 in blue. Zoom
from original magnification of 40×; (b) Laser confocal microscopy
images depicting the tissue NPs detection at t0, immediately after
i.v. injection. Note as NPs are more concentrated in heart, lung,
liver, and kidney. In the kidney image, the white dashed square indicates
the glomerulus. Nuclei are counterstain with TO-PRO3 in blue and conjugated
rhodamine-red NPs are identified by red signal. Zoom from original
magnification of 40×; (c) Representative laser confocal images
1 h after NPs injection, showing that nanoparticles (red signal) can
reach the interstitium of the organs especially the heart. Moreover,
1 h after injection, the lung showed few NPs uptake compared to the
other organs, which is in keeping with the macro-distribution analysis
in (A). Nuclei are counterstain with TO-PRO3 (in blue) and conjugated
rhodamine red-NPs were are identified in red. Zoom from original magnification
of 40×.After injection, NPs rapidly spread
in the rats being detected
first in the lungs, then in the heart, and subsequently in the spleen
and liver and, eventually, in the kidneys. Complete NPs clearance
is reached after 7 days from NPs administration, showing organ epifluorescence
signals similar to controls.Remarkably, the heart seems to
retain the greatest amount of NPs
from 1 h up to 1 day after tail-vein injection, possibly as a result
of the preferential cardiac metabolism for lipid substrates. Subsequent
accumulation in spleen, liver, and kidneys is observed, likely due
to the “filtering” ability of these organs. Lungs show
fewer NP uptake compared to the other organs, being the short-term
accumulation spike (at t0) likely due to mucociliary clearance.[60] Short-term accumulation in the heart is not
accompanied by negative effects, as confirmed by the previous NGAL
experiments and visual inspection. Confocal microscopy images of rhodamine
labeled F127@7-NPs in different tissues confirmed the
signals observed in biodistribution analyses with nanoparticles reaching
all the major organs but the spleen immediately after injection (t0) and being retained mostly by the heart, but also by liver
and spleen, after 1 h. In addition, confocal experiments performed
after 1 h also demonstrated the ability of NPs to reach the interstitium
of the organs, especially the cardiac one (Figure B).
Conclusions
We
reported a novel, biocompatible and biodegradable polymeric
nanosystem with properties remarkable for biomedical applications.
The nanoprecipitation method combined with the RODEP reaction proved
to be a very precise tool to control the nanoparticles assembly and
polymeric core formation in aqueous media. At a difference from other
poly(lipoic acid)-based nanoparticles, a one-pot preparation of loaded
and PEG-coated nanoparticles is possible, with an evident advantage
for large-scale production.As known for the nanoprecipitation
protocol, there are several
parameters that influence the formation of the nanoparticles and their
effect is often difficult to rationalize. Here, we found that besides
the volume ratios of the solution mixed, the choice of stabilizing
surfactant is apparently the crucial factor. Indeed, Pluronic F68
and F127, having very similar PEG to PPOratios, gave comparable results,
while P123 was unable to stabilize the nanoparticles. A minor role
is also played by the chemical nature of the precursors, with larger
and presumably more hydrophobic precursors forming slightly smaller
nanoparticles.The easy functionalization of lipoic acid with
various fluorophores
and their successful inclusion in the nanoparticles confirmed the
synthetic versatility of this system, which opens the possibility
of an easy doping with active species or drugs, as well as the preparation
of multifunctional systems.These nanoparticles were degradable
in the presence of thiols,
and this should entail fast payload release once taken up by cells.
Also, their degradation should result in the release of lipoic acid,
which may contribute to antioxidant cell pathways boosting the therapeutic
effects.As expected, the cell toxicity tests showed an excellent
in vitro
and in vivo biocompatibility. A remarkable and unexpected finding
was that F127-coated NP did not form any hard protein corona, and,
consistently, did not activate both the coagulation and the complement
cascade. Such an effect is superior to what is currently observed
with other PEGylated nanosystems and may give a fundamental contribution
by prolongation of the in-blood nanoparticles circulation, resulting
in more effective therapy, as well as in reducing unwanted immune
response. Another striking feature was their early (1–3 h)
accumulation in the heart in the preclinical rat model, which makes
them a candidate as suitable vectors for cardiovascular applications.All this information can be useful in the development of new patient-personalized
drug delivery systems.
Authors: Laura Maggini; Ingrid Cabrera; Amparo Ruiz-Carretero; Eko A Prasetyanto; Eric Robinet; Luisa De Cola Journal: Nanoscale Date: 2016-04-07 Impact factor: 7.790
Authors: Nancy L Benner; Rebecca L McClellan; Christopher R Turlington; Ole A W Haabeth; Robert M Waymouth; Paul A Wender Journal: J Am Chem Soc Date: 2019-05-17 Impact factor: 15.419
Authors: Francisco Silva; Alice D'Onofrio; Carolina Mendes; Catarina Pinto; Ana Marques; Maria Paula Cabral Campello; Maria Cristina Oliveira; Paula Raposinho; Ana Belchior; Salvatore Di Maria; Fernanda Marques; Carla Cruz; Josué Carvalho; António Paulo Journal: Int J Mol Sci Date: 2022-01-06 Impact factor: 5.923